argenx SE (ARGX) Plans IMNM Filing After Phase 3 Trial Met Primary Endpoint
argenx SE reported that its Phase 3 ALKIVIA trial met the primary endpoint, showing a 15.4-point improvement in TIS versus placebo. The company plans to file an FDA supplemental Biologics License Application for IMNM by the end of 2026, according to the press release.
How this was made

The 30-second read
Why it matters
The data provides a clear catalyst that could drive the stock higher ahead of the planned sBLA filing.
Market read
First disclosure of pivotal trial results for a listed biotech, likely to generate immediate price movement.
What to watch
Potential competition from other myositis therapies and the timeline for FDA review could temper upside.
Background
argenx SE announced that its Phase 3 ALKIVIA trial achieved its primary endpoint, a key milestone for its efgartigimod program.
Ticker impact
Phase 3 ALKIVIA trial met primary endpoint with significant TIS improvement, prompting a planned FDA sBLA submission.
upward pressure as market prices in the upcoming FDA filing.
First report of pivotal Phase 3 results for a listed biotech; such data historically drives strong short‑term moves.
Market effects
Boosts confidence in autoimmune myositis therapeutics and may lift peer biotech stocks.
Positive for European biotech sector, especially German‑listed companies.
Adds to the pipeline momentum for rare disease treatments worldwide.
Counterpoint
If regulatory scrutiny intensifies or data is later questioned, the rally could be short‑lived.
Key entities
- companyargenx SE
Biopharmaceutical company developing efgartigimod for autoimmune diseases.


